Viral Conjunctivitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Viral Conjunctivitis – Pipeline Review, H2 2016’, provides an overview of the Viral Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis

The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects

The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adenovir Pharma AB

NanoViricides, Inc.

Panoptes Pharma Ges.m.b.H.

Shire Plc

Starpharma Holdings Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Viral Conjunctivitis Overview 6

Therapeutics Development 7

Pipeline Products for Viral Conjunctivitis - Overview 7

Viral Conjunctivitis - Therapeutics under Development by Companies 8

Viral Conjunctivitis - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Viral Conjunctivitis - Products under Development by Companies 11

Viral Conjunctivitis - Companies Involved in Therapeutics Development 12

Adenovir Pharma AB 12

NanoViricides, Inc. 13

Panoptes Pharma Ges.m.b.H. 14

Shire Plc 15

Starpharma Holdings Limited 16

Viral Conjunctivitis - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 25

APD-209 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

APD-514 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

astodrimer - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

EKCCide-I - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

PP-001 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

SHP-640 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Viral Conjunctivitis - Dormant Projects 36

Viral Conjunctivitis - Discontinued Products 37

Viral Conjunctivitis - Product Development Milestones 38

Featured News & Press Releases 38

May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment 38

Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis 38

Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis 39

May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model 39

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development for Viral Conjunctivitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Viral Conjunctivitis – Pipeline by Adenovir Pharma AB, H2 2016 12

Viral Conjunctivitis – Pipeline by NanoViricides, Inc., H2 2016 13

Viral Conjunctivitis – Pipeline by Panoptes Pharma Ges.m.b.H., H2 2016 14

Viral Conjunctivitis – Pipeline by Shire Plc, H2 2016 15

Viral Conjunctivitis – Pipeline by Starpharma Holdings Limited, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Viral Conjunctivitis – Dormant Projects, H2 2016 36

Viral Conjunctivitis – Discontinued Products, H2 2016 37

List of Figures

List of Figures

Number of Products under Development for Viral Conjunctivitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Top 10 Targets, H2 2016 18

Number of Products by Stage and Top 10 Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports